Skip to main content

Deborah R Kaye

Associate Professor of Urology
Urology
20 Medicine Circle, Durham, NC 27710

Current Appointments & Affiliations


Associate Professor of Urology · 2025 - Present Urology, Clinical Science Departments
Associate Professor in Population Health Sciences · 2025 - Present Population Health Sciences, Basic Science Departments
Member in the Duke Clinical Research Institute · 2019 - Present Duke Clinical Research Institute, Institutes and Centers
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers
Core Faculty Member, Duke-Margolis Institute for Health Policy · 2024 - Present Duke-Margolis Institute for Health Policy, University Institutes and Centers

In the News


Published May 17, 2024
Therapies Offer New Hope for Bladder Cancers

View All News

Recent Publications


Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States.

Journal Article Health Policy Open · June 2026 BACKGROUND: Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infus ... Full text Link to item Cite

Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs.

Journal Article Am J Manag Care · September 1, 2024 OBJECTIVES: The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP) payments among all malignancies. Multiple first- ... Full text Link to item Cite

Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.

Journal Article JCO Oncol Pract · April 2023 PURPOSE: The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are often candidates for multiple first-line systemic ... Full text Link to item Cite
View All Publications

Recent Grants


Improving outcomes of patients with advanced prostate cancer through a better understanding of provider decision-making

ResearchPrincipal Investigator · Awarded by National Cancer Institute · 2022 - 2027

Decreasing the Financial Burden for Patients with Advanced Prostate Cancer By Understanding Provider Decision-Making

ResearchPrincipal Investigator · Awarded by American Urological Association Foundation · 2021 - 2022

Disparities in the Use of Oral Anticancer Agents in Kidney Cancer

ResearchCollaborator · Awarded by National Institutes of Health · 2019 - 2020

View All Grants

Education


University of Michigan, Ann Arbor · 2017 M.S.
Medical College of Wisconsin · 2010 M.D.
Washington University in St. Louis · 2002 B.A.